[Interferon therapy in hepatitis C]

Area of Science:

• Hepatology and viral gastroenterology.
• Immunology and therapeutic applications of cytokines.

Context:

• Chronic hepatitis C is a significant global health issue, leading to liver cirrhosis and hepatocellular carcinoma.
• Limited effective therapeutic options existed prior to the advent of antiviral agents and cytokine therapies.
• Hepatitis C virus (HCV) infection poses a substantial burden on public health systems worldwide.

Purpose:

• To evaluate the efficacy of Interferon-alpha (IFN-alpha) in treating chronic hepatitis C.
• To explore strategies for improving sustained virologic response rates and preventing relapse after IFN-alpha therapy.
• To investigate the potential role of IFN-alpha in managing acute hepatitis C infections.

Summary:

• IFN-alpha therapy demonstrates notable efficacy, normalizing liver transaminases in approximately 50% of patients within four weeks.
• Placebo-controlled trials confirm complete remission in about 40% of patients undergoing IFN-alpha treatment.
• Relapse following cessation of IFN-alpha therapy is frequent, necessitating further investigation into optimized dosing and treatment durations.
• Combination therapies involving IFN-alpha with other agents are being explored to enhance treatment outcomes.
• The therapeutic potential of IFN-alpha for acute hepatitis C is currently under active investigation.

Impact:

• IFN-alpha has become a cornerstone therapy for chronic hepatitis C, significantly improving patient outcomes.
• Research into optimizing IFN-alpha regimens and combination therapies continues to refine treatment protocols.
• Understanding relapse patterns informs the development of more durable treatment strategies for hepatitis C.
• The investigation into acute hepatitis C treatment broadens the clinical application of IFN-alpha.